Halozyme's PEGPH20 Program In Metastatic Pancreatic Cancer Receives Fast Track Designation
September 03, 2014 at 08:35 AM EDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track ...